Morgan Stanley
KURA icon

Morgan Stanley’s Kura Oncology KURA Stock Holding History

Morgan Stanley’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7M Sell
1,160,310
-3,667
-0.3% -$34.6K ﹤0.01% 3506
2026
Q1 		$9.46M Sell
1,163,977
-225,851
-16% -$1.94M ﹤0.01% 3609
2025
Q4 		$14.4M Sell
1,389,828
-423,236
-23% -$4.44M ﹤0.01% 3247
2025
Q3 		$16M Sell
1,813,064
-170,975
-9% -$1.22M ﹤0.01% 3097
2025
Q2 		$11.4M Buy
1,984,039
+60,881
+3% +$373K ﹤0.01% 3310
2025
Q1 		$12.7M Sell
1,923,158
-1,350,967
-41% -$10.5M ﹤0.01% 3123
2024
Q4 		$28.5M Buy
3,274,125
+2,067,411
+171% +$29.7M ﹤0.01% 2393
2024
Q3 		$23.6M Sell
1,206,714
-121,800
-9% -$2.47M ﹤0.01% 2641
2024
Q2 		$27.4M Sell
1,328,514
-28,947
-2% -$595K ﹤0.01% 2331
2024
Q1 		$29M Buy
1,357,461
+26,506
+2% +$515K ﹤0.01% 2287
2023
Q4 		$19.1M Buy
1,330,955
+1,169,992
+727% +$11.5M ﹤0.01% 2729
2023
Q3 		$1.47M Sell
160,963
-126,764
-44% -$1.29M ﹤0.01% 4579
2023
Q2 		$3.04M Buy
287,727
+76,681
+36% +$907K ﹤0.01% 4136
2023
Q1 		$2.58M Sell
211,046
-64,746
-23% -$808K ﹤0.01% 4289
2022
Q4 		$3.42M Sell
275,792
-114,716
-29% -$1.67M ﹤0.01% 4065
2022
Q3 		$5.33M Sell
390,508
-305,292
-44% -$4.71M ﹤0.01% 3632
2022
Q2 		$12.8M Buy
695,800
+250,960
+56% +$3.61M ﹤0.01% 2812
2022
Q1 		$7.15M Buy
444,840
+361,551
+434% +$5.22M ﹤0.01% 3291
2021
Q4 		$1.17M Sell
83,289
-77,738
-48% -$1.26M ﹤0.01% 4960
2021
Q3 		$3.02M Sell
161,027
-20,484
-11% -$386K ﹤0.01% 4225
2021
Q2 		$3.79M Buy
181,511
+164,609
+974% +$4.09M ﹤0.01% 4073
2021
Q1 		$478K Sell
16,902
-46,338
-73% -$1.47M ﹤0.01% 5178
2020
Q4 		$2.06M Buy
63,240
+46,607
+280% +$1.64M ﹤0.01% 4129
2020
Q3 		$509K Sell
16,633
-6,925
-29% -$153K ﹤0.01% 4632
2020
Q2 		$384K Buy
23,558
+8,874
+60% +$128K ﹤0.01% 4736
2020
Q1 		$146K Sell
14,684
-54,397
-79% -$623K ﹤0.01% 5016
2019
Q4 		$949K Buy
69,081
+41,261
+148% +$611K ﹤0.01% 4571
2019
Q3 		$423K Buy
27,820
+2,892
+12% +$51.5K ﹤0.01% 4760
2019
Q2 		$491K Buy
24,928
+4,688
+23% +$77.8K ﹤0.01% 4617
2019
Q1 		$336K Sell
20,240
-40,088
-66% -$618K ﹤0.01% 4784
2018
Q4 		$846K Buy
60,328
+5,314
+10% +$70.4K ﹤0.01% 4402
2018
Q3 		$963K Sell
55,014
-25,197
-31% -$483K ﹤0.01% 4571
2018
Q2 		$1.46M Buy
80,211
+19,211
+31% +$325K ﹤0.01% 4348
2018
Q1 		$1.15M Sell
61,000
-178,382
-75% -$3.47M ﹤0.01% 4449
2017
Q4 		$3.66M Buy
239,382
+201,626
+534% +$2.97M ﹤0.01% 3436
2017
Q3 		$565K Sell
37,756
-534,467
-93% -$5.02M ﹤0.01% 4806
2017
Q2 		$5.32M Buy
572,223
+141,795
+33% +$1.29M ﹤0.01% 2770
2017
Q1 		$3.79M Buy
430,428
+274,166
+175% +$2.01M ﹤0.01% 3159
2016
Q4 		$922K Buy
156,262
+149,372
+2,168% +$801K ﹤0.01% 4529
2016
Q3 		$43K Buy
6,890
+5,290
+331% +$26.8K ﹤0.01% 5649
2016
Q2 		$4K Buy
+1,600
New +$4.98K ﹤0.01% 6260

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Morgan Stanley's KURA Position: Q2 2026 in Review

Morgan Stanley reduced its Kura Oncology (KURA) stake by 0.32% in Q2 2026, selling an estimated $34.6K and leaving 1,160,310 shares worth $12.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3506.

Morgan Stanley first reported a position in KURA in Q2 2016 and has held it in 41 quarters since. The position peaked at $29M in Q1 2024. 220 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Morgan Stanley held 1,160,310 shares of Kura Oncology worth $12.7M as of Q2 2026.
  • Morgan Stanley sold 3,667 Kura Oncology shares in Q2 2026, an estimated $34.6K.
  • Kura Oncology made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3506 holding.
  • Morgan Stanley first reported a position in Kura Oncology in Q2 2016 and has held it in 41 quarters since.
  • Morgan Stanley's Kura Oncology position peaked at $29M in Q1 2024.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.